BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL)

BNP Paribas Financial Markets boosted its stake in Personalis, Inc. (NASDAQ:PSNL) by 53,126.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,856 shares of the company’s stock after purchasing an additional 71,721 shares during the period. BNP Paribas Financial Markets owned about 0.10% of Personalis worth $415,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. abrdn plc acquired a new stake in Personalis in the fourth quarter valued at $1,722,000. Dimensional Fund Advisors LP increased its stake in Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after purchasing an additional 242,141 shares in the last quarter. Jane Street Group LLC lifted its position in Personalis by 144.3% in the 4th quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock valued at $2,320,000 after acquiring an additional 237,033 shares in the last quarter. 683 Capital Management LLC bought a new position in shares of Personalis in the fourth quarter valued at approximately $775,000. Finally, Blue Water Life Science Advisors LP boosted its holdings in Personalis by 13.3% during the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company’s stock worth $6,548,000 after acquiring an additional 132,900 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Price Performance

NASDAQ:PSNL opened at $4.78 on Monday. The company has a market capitalization of $422.19 million, a price-to-earnings ratio of -2.85 and a beta of 1.83. Personalis, Inc. has a 1-year low of $1.14 and a 1-year high of $7.20. The business has a 50 day moving average of $3.88 and a 200 day moving average of $4.44.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The company had revenue of $20.61 million during the quarter, compared to analysts’ expectations of $17.41 million. As a group, sell-side analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PSNL shares. Guggenheim started coverage on Personalis in a research report on Thursday, May 15th. They set a “buy” rating and a $6.00 price target for the company. Craig Hallum started coverage on shares of Personalis in a report on Monday, March 17th. They issued a “buy” rating and a $8.00 price objective for the company. HC Wainwright upped their price target on Personalis from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $7.67.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.